EA201592172A1 - Проглатываемые таблетки n-ацетилцистеина - Google Patents

Проглатываемые таблетки n-ацетилцистеина

Info

Publication number
EA201592172A1
EA201592172A1 EA201592172A EA201592172A EA201592172A1 EA 201592172 A1 EA201592172 A1 EA 201592172A1 EA 201592172 A EA201592172 A EA 201592172A EA 201592172 A EA201592172 A EA 201592172A EA 201592172 A1 EA201592172 A1 EA 201592172A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tablets
acetylcestein
pastable
acetylcysteine
nac
Prior art date
Application number
EA201592172A
Other languages
English (en)
Other versions
EA031856B1 (ru
Inventor
Алессандра Де Лаццари
Альберто Моретто
Original Assignee
Замбон С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48748383&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201592172(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Замбон С.П.А. filed Critical Замбон С.П.А.
Publication of EA201592172A1 publication Critical patent/EA201592172A1/ru
Publication of EA031856B1 publication Critical patent/EA031856B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится к проглатываемым таблеткам, содержащим по меньшей мере 80 мас.% N-ацетилцистеина (NAC) и по меньшей мере одно фармацевтически приемлемое вспомогательное вещество, в частности таблеткам, в которых отсутствует сернистый запах, отличающимся тем, что указанные таблетки получают с использованием гранулята, полученного посредством способа сухого гранулирования активного ингредиента отдельно, с которым смешивают вспомогательные вещества перед прессованием.
EA201592172A 2013-05-29 2014-05-27 Проглатываемая таблетка n-ацетилцистеина EA031856B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000874A ITMI20130874A1 (it) 2013-05-29 2013-05-29 Compresse deglutibili di n-acetilcisteina
PCT/EP2014/060950 WO2014191410A1 (en) 2013-05-29 2014-05-27 Swallowable n-acetylcysteine tablets

Publications (2)

Publication Number Publication Date
EA201592172A1 true EA201592172A1 (ru) 2016-05-31
EA031856B1 EA031856B1 (ru) 2019-03-29

Family

ID=48748383

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201592172A EA031856B1 (ru) 2013-05-29 2014-05-27 Проглатываемая таблетка n-ацетилцистеина

Country Status (29)

Country Link
US (1) US9808427B2 (ru)
EP (1) EP3003278B1 (ru)
JP (1) JP6438013B2 (ru)
CN (1) CN105228595B (ru)
AU (1) AU2014273148B2 (ru)
BR (1) BR112015029038B1 (ru)
CA (1) CA2911474C (ru)
CY (1) CY1122114T1 (ru)
DK (1) DK3003278T3 (ru)
EA (1) EA031856B1 (ru)
ES (1) ES2721649T3 (ru)
HR (1) HRP20190687T1 (ru)
HU (1) HUE044880T2 (ru)
IL (1) IL242439B (ru)
IT (1) ITMI20130874A1 (ru)
LT (1) LT3003278T (ru)
MX (1) MX366917B (ru)
MY (1) MY174005A (ru)
PE (1) PE20160184A1 (ru)
PH (1) PH12015502608B1 (ru)
PL (1) PL3003278T3 (ru)
PT (1) PT3003278T (ru)
RS (1) RS58653B1 (ru)
SG (2) SG10201709861YA (ru)
SI (1) SI3003278T1 (ru)
TR (1) TR201906101T4 (ru)
UA (1) UA117829C2 (ru)
WO (1) WO2014191410A1 (ru)
ZA (1) ZA201508411B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201991331A1 (ru) 2016-12-15 2019-11-29 N-ацетилцистеин для применения в качестве антибактериального агента
IT201700109080A1 (it) * 2017-09-28 2019-03-28 Neilos S R L Composizione per la prevenzione e/o il trattamento delle affezioni delle vie respiratorie
WO2019086408A1 (en) * 2017-11-02 2019-05-09 Zambon S.P.A. Pharmaceutical compositions comprising safinamide
US10288629B1 (en) * 2017-12-19 2019-05-14 Aeterna Zentaris, Inc. Method of assessing growth hormone deficiency in humans by a macimorelin containing composition
WO2019238647A1 (en) * 2018-06-14 2019-12-19 Poxel Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes
IT201800007928A1 (it) * 2018-08-07 2020-02-07 Sofar Spa Composizione contenente un agente mucolitico per il trattamento di ipersecrezione di muco e dispositivo per il suo dosaggio
CN112843008A (zh) * 2021-02-07 2021-05-28 广东赛康制药厂有限公司 一种乙酰半胱氨酸片及其制备方法
CN114886860B (zh) * 2022-06-28 2023-04-25 山东达因海洋生物制药股份有限公司 一种乙酰半胱氨酸药物组合物及其制剂和制备工艺

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0481294B2 (de) * 1990-10-19 2001-04-11 Spirig Ag Pharmazeutische Präparate Feste, schnell-lösliche Arzneimittelzubereitung enthaltend N-Acetylcystein
GB9305058D0 (en) * 1993-03-12 1993-04-28 Penn Pharm Ltd Pharmaceutical compositions
IT1311907B1 (it) 1999-04-06 2002-03-20 Zambon Spa Compresse deglutibili ad alto contenuto di n-acetilcisteina.
US6623754B2 (en) * 2001-05-21 2003-09-23 Noveon Ip Holdings Corp. Dosage form of N-acetyl cysteine
JP2003155232A (ja) * 2001-09-07 2003-05-27 Takeda Chem Ind Ltd 不快な臭いが低減されたｌ−システイン配合固形製剤およびその製造方法
US20080139654A1 (en) * 2006-12-09 2008-06-12 Eric Mott Soderling Acetaminophen compositions having minimized side effects including reduced hepatotoxicity
IT1399492B1 (it) * 2010-04-13 2013-04-19 Alpex Pharma Sa Composizioni farmaceutiche effervescenti contenenti n-acetilcisteina.
EP2574333B1 (en) * 2011-09-27 2017-01-11 Friulchem SpA N-acetylcysteine effervescent tablet and its therapeutical applications

Also Published As

Publication number Publication date
CN105228595A (zh) 2016-01-06
HUE044880T2 (hu) 2019-11-28
WO2014191410A1 (en) 2014-12-04
CN105228595B (zh) 2019-01-04
EA031856B1 (ru) 2019-03-29
EP3003278B1 (en) 2019-02-27
PL3003278T3 (pl) 2019-07-31
AU2014273148A1 (en) 2015-11-26
AU2014273148B2 (en) 2019-02-28
ZA201508411B (en) 2022-03-30
MX366917B (es) 2019-07-30
BR112015029038A2 (pt) 2017-07-25
CA2911474C (en) 2021-04-13
PT3003278T (pt) 2019-05-14
JP2016520108A (ja) 2016-07-11
US9808427B2 (en) 2017-11-07
LT3003278T (lt) 2019-05-10
SI3003278T1 (sl) 2019-08-30
PH12015502608A1 (en) 2016-02-29
IL242439B (en) 2020-01-30
ES2721649T3 (es) 2019-08-02
HRP20190687T1 (hr) 2019-06-14
JP6438013B2 (ja) 2018-12-12
PE20160184A1 (es) 2016-04-27
SG10201709861YA (en) 2018-01-30
MY174005A (en) 2020-03-03
TR201906101T4 (tr) 2019-05-21
EP3003278A1 (en) 2016-04-13
PH12015502608B1 (en) 2016-02-29
UA117829C2 (uk) 2018-10-10
SG11201509177VA (en) 2015-12-30
MX2015016130A (es) 2016-08-08
CY1122114T1 (el) 2020-07-31
BR112015029038B1 (pt) 2022-12-06
DK3003278T3 (da) 2019-05-06
RS58653B1 (sr) 2019-05-31
ITMI20130874A1 (it) 2014-11-30
US20160113876A1 (en) 2016-04-28
CA2911474A1 (en) 2014-12-04

Similar Documents

Publication Publication Date Title
EA201592172A1 (ru) Проглатываемые таблетки n-ацетилцистеина
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201692043A1 (ru) Лекарственная форма иммунодепрессанта
EA201690810A1 (ru) Мягкие пастилки, содержащие экстракт куркумы
EA201500245A1 (ru) Твердый фармацевтический препарат, который содержит левотироксин
TN2015000135A1 (en) Modified release formulations for oprozomib
BR112013008749A2 (pt) análogos de ciclosporina
CO2017007316A2 (es) Formulación farmacéutica
EA201591717A1 (ru) Твердые формы гидрохлорида вемурафениба
EA202090913A1 (ru) Композиция таблеток с модифицированным высвобождением, содержащая мирабегрон
EA201690216A1 (ru) Фармацевтические композиции ранолазина и дронедарона
EA201890477A1 (ru) Инкапсулированная композиция финголимода
EA201690395A1 (ru) Стабильная фармацевтическая композиция, содержащая бисопролол и рамиприл
CL2016000182A1 (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
CL2016000183A1 (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido redispersable que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
MX2020007326A (es) Regimen de dosificacion de siponimod.
BR112016007031A8 (pt) composição farmacêutica oral sólida, processo para preparar a composição farmacêutica oral sólida, e uso de uma composição farcêutica oral sólida
EA201600242A1 (ru) Фармацевтическая композиция в форме таблетки и способ ее получения
EA201691422A1 (ru) Перорально распадающиеся таблетированные составы мемантина
BR112013000870A2 (pt) forma de dosagem farmacêutica oral em comprimidos
PE20151432A1 (es) Formulaciones de lorazepam de liberacion sostenida
EA201791794A1 (ru) Лекарственная форма препарата рацекадотрил
RS54692B1 (en) PHARMACEUTICAL COMPOSITION COVERING (S) -2- (OXOPYROLIDIN-1-IL) BUTANAMIDE
EA201800197A1 (ru) Способ получения фармацевтической композиции в форме таблеток, содержащих в качестве действующего вещества абиратерона ацетат, и фармацевтическая композиция